NASDAQ:SLXN Silexion Therapeutics (SLXN) Stock Price, News & Analysis $2.79 +0.23 (+8.98%) (As of 11/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends About Silexion Therapeutics Stock (NASDAQ:SLXN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silexion Therapeutics alerts:Sign Up Key Stats Today's Range$2.31▼$3.0050-Day Range$0.21▼$2.7952-Week Range$1.86▼$41.85Volume361,569 shsAverage Volume1.21 million shsMarket Capitalization$4.46 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingBuy Company OverviewSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive SLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLXN Stock News HeadlinesSilexion Therapeutics Corp trading halted, news pendingNovember 27, 2024 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-9 Reverse Share SplitNovember 23, 2024 | finanznachrichten.deUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonDecember 1, 2024 | Porter & Company (Ad)Silexion Therapeutics Announces 1-for-9 Reverse Share SplitNovember 22, 2024 | globenewswire.com5 Stocks Retail Investors Are Most Bullish On At Mid-DayNovember 20, 2024 | msn.comWhat's Going On With Silexion Therapeutics Shares Wednesday?November 20, 2024 | benzinga.comSilexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity ConferenceNovember 20, 2024 | globenewswire.comPromising Therapeutic Advances and Strategic Positioning Make Silexion Therapeutics a Compelling Investment OpportunityNovember 17, 2024 | markets.businessinsider.comSee More Headlines SLXN Stock Analysis - Frequently Asked Questions How have SLXN shares performed this year? Silexion Therapeutics' stock was trading at $1.47 at the beginning of 2024. Since then, SLXN stock has increased by 89.8% and is now trading at $2.79. View the best growth stocks for 2024 here. When did Silexion Therapeutics' stock split? Silexion Therapeutics's stock reverse split on Friday, November 29th 2024. The 1-9 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. Who are Silexion Therapeutics' major shareholders? Top institutional investors of Silexion Therapeutics include Wildcat Capital Management LLC (7.38%). How do I buy shares of Silexion Therapeutics? Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Silexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU). Company Calendar Today11/30/2024Next Earnings (Estimated)12/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SLXN CUSIPN/A CIK2022416 Websilexion.com Phone972-2-674-3430Fax212-572-6395EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside-64.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$260,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-249.43% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.67 per share Price / Cash Flow4.19 Book Value($0.32) per share Price / Book-8.72Miscellaneous Outstanding Shares14,428,000Free Float9,667,000Market Cap$40.25 million OptionableN/A Beta-0.11 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:SLXN) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredThe Trump Surge-SectorsIt's already responsible for the greatest stock market achievements in history. It predicted President Trump's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
